Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Employees of Juno received a surprise in their Monday morning emails.
The latest acquisition makes it the highest amount paid for a flex R&D building in Los Angeles County.
The year is already off to a good start with mergers and acquisitions in the biopharma industry.
Sinocare of Changsha may bid as much as $4B to acquire J&J’s diabetes medical device subsidiaries
Most investors and analysts are expecting 2018 to be a big year for mergers and acquisitions.
The deal has Sanofi paying $105 per share in cash.
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26.
A look at whether the new tax reform will really spur a M&A spending spree for drugmakers.
The company believes its ultrasensitive immunoassay technology is well-suited to pharma research.
Immune Design is a clinical-stage immunotherapy company.